# Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study

> **NCT07663071** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 44 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **DRUG:** Short-course radiotherapy combined with Retlirafusp alfa and CAPOX chemotherapy

## Key facts

- **NCT ID:** NCT07663071
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-05-27
- **Primary completion:** 2028-05-27
- **Final completion:** 2029-05-27
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663071, "Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*